Imputing Russian ability to Manipulate Data at Russian
Imputing Russian ability to Manipulate Data at Russian sites... is a "WELL DONE NOTHING BURGER". Otherwise, FDA would not have approved IPIX Trial protocol and site selection!
Quote:
' You gonna trust letting Russia run most of our trial sites?
Russian Trials... are done with random FDA "site review".
The FDA confirms MO as compliant with FDA standards...and approval by FDA makes the quoted comment above and its inference... baseless.
The RAW results of the trials in Russia and the U.S. (blood samples, etc)...data is assembled and shipped by the US Supervised CRO at the site, then forwarded, assembled, and scrubbed at the US or EU Lab chosen by U.S Supervising CRO outside Russia...that information is received off-site and is entered by FDA approved Data Computer company, which generates computer data for analysis...none of the scrubbing, assembly, and data entry is a function of a Russian (or US) Clinical Trial site...
The ultimate CRO Supervisor (engaged by IPIX) in the U.S. The sub-CRO engaged in Russia by U.S. CRO causes the delivery of raw information to or under direction and review of Supervisory CRO...to western labs...not Russian labs.
Nothing to fret about here...process and ALL CROs were disclosed by FDA when IPIX received approval for trials...
KNOW WHAT YOU OWN...and Just hold on to what you have...everything will come out in the wash...when Trial Results reported, IMO, in days...
7
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Pioneering a New Standard in Homecare Take a gander at Angels on Call Homecare. They're not just another name in a crowded field; they've carved out a niche—specializing in elite care for Dementia and Parkinson's patients. You don't usually hear homecare and innovation in the same breath, do you? But these folks are setting a fresh benchmark. Independent feedback has...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...
Continue Reading
The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...
Continue Reading
The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...
Continue Reading
Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...
Continue Reading
New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...
Continue Reading
Welcome To Venue Two Eleven: Where History Meets Modernity Alright, folks. Let’s talk about Venue Two Eleven—a new joint in town that’s blending the old with the new in a way that’s got me raising an eyebrow and maybe even sipping my coffee a little slower. Nestled in the Museum of the Oregon Territory, this place is pulling double duty as both a window to the...
Continue Reading
Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...
Continue Reading
Top 5 Most Recently Viewed Articles
Akeso Moves Forward with Promising Cancer Therapy Trials Akeso Biopharma is excited to share fantastic news regarding its latest clinical endeavors in the realm of cancer treatment. The company has successfully enrolled the first patient in the AK112-309 trial, a pivotal Phase III study designed to evaluate the efficacy of ivonescimab in combination with another regimen...
Continue Reading
Quanex Building Products Announces Quarterly Dividend HOUSTON — Quanex Building Products Corporation (NX) is pleased to announce that its Board of Directors declared a quarterly cash dividend of $0.08 per share on its common stock. This dividend is scheduled to be paid to shareholders of record on a specified date, indicating the company's commitment to rewarding its...
Continue Reading
Trump Demands Drug Firms Reveal COVID Vaccine Data Former President Donald Trump has issued a call to pharmaceutical companies to provide concrete evidence regarding the effectiveness of their COVID-19 drugs, particularly emphasizing the need for transparency surrounding their vaccine data. Transparency in Pharmaceuticals On his social media platform, Trump urged these...
Continue Reading
AECOM Technology Stock Peaks at $108.26 AECOM Technology Corporation has recently achieved a major milestone in the stock market, reaching an impressive high of $108.26. This achievement not only reflects the robust growth of the infrastructure consulting firm but also represents a 43.14% increase in its stock value over the past year. Investors have been showing strong...
Continue Reading
China Resumes U.S. Soybean Purchases Amid Market Changes Recent reports indicate that China has made its initial purchase of U.S. soybeans from the current year’s harvest, marking the end of a prolonged boycott. This significant development comes just ahead of a highly anticipated summit between U.S. President Donald Trump and Chinese President Xi Jinping. Market...
Continue Reading